Perrigo Company plc Tax Withholding Paid on Stock Awards
Perrigo Company plc (PRGO) reported Tax Withholding Paid on Stock Awards of $7.00 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- Perrigo Company plc payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-27 was $4.20M, a 27.59% decline year-over-year.
- Perrigo Company plc payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-28 was $2.80M, a 76.47% decline year-over-year.
- Perrigo Company plc payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $300.00K, a 40.00% decline year-over-year.
- Perrigo Company plc payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-27 was $1.10M.
- Perrigo Company plc payment, tax withholding, share-based payment arrangement for fiscal 2025 was $19.10M, a 23.23% increase from fiscal 2024.
- Perrigo Company plc payment, tax withholding, share-based payment arrangement for fiscal 2024 was $15.50M, a 17.55% decline from fiscal 2023.
- Perrigo Company plc payment, tax withholding, share-based payment arrangement for fiscal 2023 was $18.80M.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-27 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $7.00M 10-Q · filed 2026-08-05 | $7.30M derived: sum of 3 quarters · filed 2026-08-05 | $8.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $2.80M 10-Q · filed 2026-05-06 | $3.10M derived: sum of 2 quarters · filed 2026-05-06 | $4.20M derived: sum of 3 quarters · filed 2026-05-06 | $10.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.40M derived: sum of 2 quarters · filed 2026-02-26 | $7.20M derived: sum of 3 quarters · filed 2026-08-05 | $19.10M 10-K · filed 2026-02-26 |
| 2025-09-27 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.90M derived: sum of 2 quarters · filed 2026-08-05 | $18.80M 10-Q · filed 2025-11-05 | $19.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $5.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $17.70M 10-Q · filed 2026-08-05 | $18.20M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-03-29 | $11.90M 10-Q · filed 2026-05-06 | $12.40M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.50M 10-K · filed 2026-02-26 | ||
| 2024-09-28 | $15.00M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $18.80M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |